Legend Biotech Corp
LEGN34.600USD
-0.960-2.70%
Fechamento 08/25, 16:00（ET）Cotações atrasadas em 15 min
6.39BValor de mercado
PerdaP/L TTM
Mais detalhes de Legend Biotech Corp Empresa
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Informações da empresa
Código da empresaLEGN
Nome da EmpresaLegend Biotech Corp
Data de listagemJun 04, 2020
CEODr. Ying Huang, Ph.D.
Número de funcionários2600
Tipo de títulosDepository Receipt
Fim do ano fiscalJun 04
Endereço2101 Cottontail Lane
CidadeSOMERSET
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal08873
Telefone17328505598
Sitehttps://investors.legendbiotech.com/
Código da empresaLEGN
Data de listagemJun 04, 2020
CEODr. Ying Huang, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Director
Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Wai Man (Philip) Yau, CPA
Mr. Wai Man (Philip) Yau, CPA
Independent Director
Independent Director
--
--
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
Dr. Fangliang (Frank) Zhang, Ph.D.
Dr. Fangliang (Frank) Zhang, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Director
Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
168.29M
86.28%
Europe
26.67M
13.67%
China
90.00K
0.05%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
12.53%
Westfield Capital Management Company, L.P.
3.51%
HHLR Advisors, Ltd.
3.36%
Suvretta Capital Management, LLC
2.04%
Deerfield Management Company, L.P.
1.60%
Outro
76.95%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
12.53%
Westfield Capital Management Company, L.P.
3.51%
HHLR Advisors, Ltd.
3.36%
Suvretta Capital Management, LLC
2.04%
Deerfield Management Company, L.P.
1.60%
Outro
76.95%
Tipos de investidores
Investidores
Proporção
Investment Advisor
22.26%
Investment Advisor/Hedge Fund
13.70%
Hedge Fund
8.80%
Corporation
1.22%
Research Firm
1.12%
Venture Capital
0.59%
Pension Fund
0.37%
Bank and Trust
0.31%
Insurance Company
0.16%
Outro
51.46%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
545
89.45M
48.54%
-25.68M
2025Q1
566
91.15M
49.68%
-26.78M
2024Q4
546
104.37M
56.89%
-4.12M
2024Q3
521
96.19M
52.43%
-11.10M
2024Q2
501
96.66M
52.77%
-1.31M
2024Q1
490
91.55M
50.22%
-3.47M
2023Q4
482
91.08M
50.06%
-4.11M
2023Q3
468
90.50M
49.93%
-2.81M
2023Q2
459
88.99M
49.23%
+9.84M
2023Q1
421
72.14M
43.70%
-3.07M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
11.26M
6.11%
-452.89K
-3.87%
Mar 31, 2025
Westfield Capital Management Company, L.P.
6.92M
3.75%
+1.20M
+21.07%
Mar 31, 2025
HHLR Advisors, Ltd.
5.98M
3.25%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
3.75M
2.03%
+253.73K
+7.26%
Mar 31, 2025
Deerfield Management Company, L.P.
1.74M
0.95%
+191.84K
+12.36%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.11M
1.69%
-148.24K
-4.55%
Mar 31, 2025
Braidwell LP
2.98M
1.62%
--
--
Mar 31, 2025
Fidelity Institutional Asset Management
1.95M
1.06%
+210.09K
+12.08%
Mar 31, 2025
Genscript Biotech Corp
2.25M
1.22%
--
--
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: qua, 6 de ago
Atualizado em: qua, 6 de ago
Nome
Proporção
Matthews Emerging Markets Discovery Active ETF
5.64%
Matthews Emerging Markets Sustainable Future Active ETF
5.48%
Harbor Health Care ETF
5.3%
Global X Genomics & Biotechnology ETF
4.29%
Tema Oncology ETF
3.01%
Virtus LifeSci Biotech Products ETF
1.99%
KraneShares MSCI All China Health Care Index ETF
1.68%
iShares Biotechnology ETF
0.46%
WisdomTree China ex-State-Owned Enterprises Fund
0.34%
Invesco Nasdaq Biotechnology ETF
0.32%
Ver Mais
Matthews Emerging Markets Discovery Active ETF
Proporção5.64%
Matthews Emerging Markets Sustainable Future Active ETF
Proporção5.48%
Harbor Health Care ETF
Proporção5.3%
Global X Genomics & Biotechnology ETF
Proporção4.29%
Tema Oncology ETF
Proporção3.01%
Virtus LifeSci Biotech Products ETF
Proporção1.99%
KraneShares MSCI All China Health Care Index ETF
Proporção1.68%
iShares Biotechnology ETF
Proporção0.46%
WisdomTree China ex-State-Owned Enterprises Fund
Proporção0.34%
Invesco Nasdaq Biotechnology ETF
Proporção0.32%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
